-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Traditional Chinese medicine has accumulated a lot of clinical experience in the diagnosis and treatment of coronary heart disease, but there is always a lack of large-scale evidence-based medical research to support its efficacy.
In 2011, academician Ge Junbo from Zhongshan Hospital Affiliated to Fudan University and Professor Fan Weihu from Huashan Hospital Affiliated to Fudan University carried out a large-scale evidence-based study of traditional Chinese medicine—MUST study of Shexiang Baoxin Pills, which is in line with international standards.
Academician Chen Keji of Yuan Hospital serves as the chairman of the independent endpoint event review committee.
The MUST study ended perfectly after ten years.
The MUST study results were published in the "Chinese Medical Journal" in January 2021.
On April 18, a press conference on the MUST research results of Shexiang Baoxin Pills was held in Shanghai.
Inheriting classics, evidence-based navigation
MUST research helps the development of traditional Chinese medicine
Academician Ge Junbo
Academician Ge Junbo, chairman of the conference, expressed his sincere gratitude to the colleagues.
Academician Chen Keji
Academician Chen Keji said: "The MUST study has confirmed the safety and effectiveness of Shexiang Baoxin Pills through evidence-based medicine.
Academician Zhang Boli
Academician Zhang Boli mentioned: "First of all congratulations to Academician Ge Junbo for achieving such a good result in the MUST study.
Academician Chen Kaixian
Academician Chen Kaixian mentioned: "In recent years, the party and the state have attached great importance and strong support to the development of the Chinese medicine industry, and clinical evidence-based research is one of the core methods.
Building a high building, a monument
MUST study and sing the legend of TCM evidence-based medicine
Chaired by Professor Huo Yong from Peking University First Hospital, Academician Ge Junbo, chairman of the conference, introduced the design and latest results of the MUST study-the MUST study is a multi-center, double-blind, randomized, placebo-controlled study, and the study design is based on A large number of international clinical studies finally included a total of 2673 patients with stable coronary heart disease, followed up for 2 years, covering 22 provinces, municipalities and autonomous regions across the country, a total of 97 tertiary hospitals participated, and all endpoints were independent endpoints led by Academician Chen Keji The event review committee was conducted, and the study was registered for clinical trials in both China and the United States.
The results of the MUST study showed that on the basis of taking aspirin and statins, patients with stable coronary heart disease who added Shexiang Baoxin Pills had a 26.
The MUST study confirmed that long-term use of Shexiang Baoxin Pills can significantly improve the stability of angina pectoris and the attack frequency score, which means that Shexiang Baoxin Pills can effectively alleviate the symptoms of patients and significantly improve the quality of life of patients.
Conclusion
The conference ended successfully in the heated discussion of the participating experts.
